Filgotinib Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 100 mg, 200 mg
Reference Brands: Jyseleca(EU)
Category:
Arthritis
Filgotinib inhibits Janus kinase 1 (JAK1), blocking cytokine signaling involved in inflammation. It reduces joint pain, swelling, and disease progression in rheumatoid arthritis. Benefits include rapid symptom relief, improved joint function, and better quality of life, with an oral formulation offering convenient long-term management of autoimmune conditions.
Filgotinib tablets is available in Tablets
and strengths such as 100 mg, 200 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Filgotinib tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Filgotinib tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Filgotinib tablets are approved in the EU for rheumatoid arthritis, with the brand Jyseleca regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval is pending or under review, as it is not yet marketed. Both regions require detailed dossiers for approval and ongoing pharmacovigilance. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support efficient market access for filgotinib tablets, ensuring adherence to European standards for safe, effective treatment of autoimmune diseases, helping navigate complex regulatory landscapes seamlessly.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing